Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

Gilead in 2021 won the FDA accelerated nod for Trodelvy in metastatic urothelial cancer, but continued approval was contingent on the outcome of a confirmatory study. The company in late May said that ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Cheniere Energy moved one step closer to producing first liquefied natural gas from a Corpus Christi, Texas, expansion ...

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi ... and breast and bladder cancer therapy Trodelvy (from Immunomedics). Market Capitalization Analysis: With a ...

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer ... AZ said that the withdrawal is aligned with FDA post-approval ...

Following a consultation with the US Food and Drug ... withdraw the US indication of atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC bladder ...

Cancer Screening Guidelines Validated for Dermatomyositis Most of the cancers were detected using standard age- and sex-based cancer screenings, suggesting the potential for overscreening in this ...